Table 2 Ingenuity pathway analysis BioProfiler results showing genes significantly differentially expressed by sex in TARGET-OS that have existing chemotherapies for other cancers
Gene | Molecule Type | Higher gene expression | Differential gene expression, p value | Cancers known to be associated with the gene | Drug trials for particular condition associated with this gene |
|---|---|---|---|---|---|
ACHE | Enzyme | Males | 0.005 | Brain tumor, leukemia, lung cancer | Phase 3 |
C3 | Peptidase | Females | 0.01 | Neuroblastoma, Langerhans cell histiocytosis, leukemia | Approved, phase 2/3, phase 3 |
CD3D | Transmembrane receptor | Females | 0.006 | B cell acute lymphoblastic lymphoma, lymphoblastic B cell lymphoma | Approved, phase 2/3, phase 3 |
CD3E | Transmembrane receptor | Females | 0.009 | B cell acute lymphoblastic lymphoma, B cell acute lymphoblastic leukemia | Approved, phase 2/3, phase 3 |
CDK4 | Kinase | Females | 0.02 | Breast cancer, soft tissue sarcoma, lung cancer, melanoma | Approved, phase 2/3, phase 3, phase 4 |
CEACAM5 | Other | Females | 0.04 | Lung cancer | Phase 3 |
CHRNA7 | Transmembrane receptor | Males | 0.03 | Bladder cancer | Phase 4 |
CYP19A1 | Enzyme | Females | 0.02 | Breast cancer, fallopian tube neoplasm, ovarian carcinoma, serous peritoneal adenocarcinoma, leiomyoma, uterine cancer | Approved, phase 2/3, phase 3, phase 4 |
FCGR3A/FCGR3B | Transmembrane receptor | Females | 0.009 | Neuroblastoma, Langerhans cell histiocytosis, leukemia | Approved, phase 2/3, phase 3 |
FLT3 | Kinase | Females | 0.03 | Chronic myelogenous leukemia, acute myeloid leukemia, acute myeloid leukemia associated with myelodysplastic syndrome, non-small cell lung cancer, colorectal adenocarcinoma, hepatocellular carcinoma, renal cell carcinoma, advanced stage gastrointestinal stromal tumor, pancreatic neuroendocrine tumor | Approved, phase 2/3, phase 3, phase 4 |
FSHR | G-protein coupled receptor | Females | 0.04 | Prostate cancer | Phase 3 |
HTR3B | Ion channel | Females | 0.03 | Pancreatic cancer | Phase 2/3 |
ICOS | Transmembrane receptor | Females | 0.008 | Head and neck cancers | Phase 3 |
IL5 | Cytokine | Females | 0.04 | Nasal polyp | Phase 3 |
KCNC1 | Ion channel | Males | 0.0003 | Prostate cancer | Phase 4 |
KCND2 | Ion channel | Females | 0.01 | Prostate cancer | Phase 4 |
LCK | Kinase | Females | 0.04 | Chronic myelogenous leukemia, acute lymphoblastic leukemia, angiosarcoma, non-small cell lung carcinoma, renal cell carcinoma, soft tissue sarcoma, epithelioid malignant pleural mesothelioma, extraskeletal osteosarcoma, leiomyosarcoma, colorectal adenocarcinoma, sarcoma, malignant peripheral nerve sheath tumor, malignant soft tissue neoplasm, cancer, chondrosarcoma, ovarian cancer, colorectal adenocarcinoma, soft tissue sarcoma, melanoma, synovial sarcoma | Approved, phase 2/3, phase 3, phase 4 |
MUC16 | Other | Females | 0.03 | Ovarian cancer | Phase 3 |
PLA2G2A | Enzyme | Females | 0.03 | Advanced oral squamous cell carcinoma, colorectal cancer, Langerhans cell histiocytosis, primary oral squamous cell carcinoma, soft palate squamous cell carcinoma | Phase 2/3, phase 3, phase 4 |
ROS1 | Kinase | Females | 0.03 | Lung cancer, hepatocellular carcinoma, renal cell carcinoma, soft tissue sarcoma, T cell lymphoma, myofibroblastic tumor, neuroblastoma, gastrointestinal carcinoid tumor, neuroendocrine malignant tumor, pancreatic endocrine tumor, thyroid cancer, pancreatic neuroendocrine tumor, melanoma | Approved, phase 2/3, phase 3, phase 4 |
TGFB2 | Growth factor | Males | 0.04 | Anaplastic astrocytoma, glioblastoma | Phase 3 |
TNFRSF8 | Transmembrane receptor | Males | 0.001 | Hodgkin lymphoma, T cell lymphoma, anaplastic large cell lymphoma | Approved, phase 3, phase 4 |
TP53 | Transcription regulator | Females | 0.0002 | Myelodysplastic syndrome | Phase 3 |
TUBB4A | Other | Males | 0.02 | Anaplastic glioma, anaplastic oligodendroglioma, glioma, B cell-like diffuse large B cell lymphoma, acute lymphoblastic leukemia, lymphoma, acute myeloid leukemia, non-small cell lung cancer, ovarian cancer, d breast cancer, cervical cancer, cholangiocarcinoma, endometrial carcinoma, esophageal cancer, fallopian tube cancer, follicular B cell or T cell lymphoma, gastric adenocarcinoma, pancreatic cancer, prostate cancer, sarcoma, soft tissue sarcoma, testicular carcinoma, bladder carcinoma, AIDS-related Kaposi sarcoma, anaplastic astrocytoma, anaplastic medulloblastoma, angiosarcoma | Approved, phase 2/3, phase 3, phase 4 |